0001004878-17-000183.txt : 20171101
0001004878-17-000183.hdr.sgml : 20171101
20170808112938
ACCESSION NUMBER: 0001004878-17-000183
CONFORMED SUBMISSION TYPE: CORRESP
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20170808
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: CEL SCI CORP
CENTRAL INDEX KEY: 0000725363
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 840916344
STATE OF INCORPORATION: CO
FISCAL YEAR END: 0930
FILING VALUES:
FORM TYPE: CORRESP
BUSINESS ADDRESS:
STREET 1: 8229 BOONE BLVD .
STREET 2: SUITE 802
CITY: VIENNA
STATE: VA
ZIP: 22182
BUSINESS PHONE: 7035069460
MAIL ADDRESS:
STREET 1: 8229 BOONE BLVD.
STREET 2: SUITE 802
CITY: VIENNA
STATE: VA
ZIP: 22182
FORMER COMPANY:
FORMER CONFORMED NAME: INTERLEUKIN 2 INC
DATE OF NAME CHANGE: 19880317
CORRESP
1
filename1.txt
CEL-SCI CORPORATION
8229 Boone Blvd. #802
Vienna, VA 22182
(703) 506-9460
August 7, 2017
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, DC 20549
Re: CEL-SCI Corporation
Form S-1
SEC File No. 333-219368
CEL-SCI Corporation (the "Company") requests that the effective date of the
above captioned Registration Statement be accelerated to Thursday, August 10,
2017, 11:00 a.m. Eastern time, or as soon as practicable thereafter.
The Company understands that:
o should the Commission or the staff, acting pursuant to delegated
authority, declare the filing effective, it does not foreclose the
Commission from taking any action with respect to the filing;
o the action of the Commission or the staff, acting pursuant to
delegated authority, in declaring the filing effective, does not
relieve the Company from its full responsibility for the adequacy and
accuracy of the disclosure in the filing; and
o the Company may not assert this action as defense in any proceedings
initiated by the Commission or any person under the federal securities
laws of the United States.
Very Truly Yours,
/s/ Patricia B. Prichep
Patricia B. Prichep,
Senior Vice President of Operations